| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 6.9K | 12.1% | 30.3% |
| Total Income | 7.0K | 11.9% | 31.0% |
| Expenditure | 5.5K | 22.8% | 33.7% |
| PBT | 1.4K | 19.8% | 14.3% |
| Net Profit | 1.0K | 17.4% | 0.3% |
| OPM | 25.22% | 7.14pp | 8.79pp |
| NPM | 14.66% | 5.21pp | 4.20pp |
| EPS | 10.36 | 17.2% | 1.8% |
Zydus Lifesciences Announces Q3 & 9M FY26 Financial Results: Revenue Up 30% and 17% Respectively
09 Feb 2026 · 9 Feb, 1:53 pm
Summary
Zydus Lifesciences Ltd. announced its unaudited consolidated financial results for the quarter and nine months ended December 31, 2025. The company reported a 30% YoY increase in revenue from operations for Q3 FY26 and a 17% YoY increase for 9M FY26. EBITDA for Q3 FY26 was up 31% YoY and EBITDA margin stood at 26.5%. Net Profit (Adjusted) for Q3 FY26 was up 9% YoY. Capex (organic) for the quarter was Rs. 4,637 mn. For 9M FY26, EBITDA was up 20% YoY, EBITDA margin stood at 30.3%, and Net Profit (Adjusted) was up 15% YoY. Capex (organic) for the nine months was Rs. 13,568 mn. The Net Debt to Equity ratio as on 31st December 2025 was 0.11x while Net Debt to EBITDA stood at 0.36x at the end of December 2025.
Key Highlights
- 1
Revenue from operations at Rs. 68,645 mn, up 30% over last year for Q3 FY26
- 2
Revenue from operations at Rs. 195,614 mn, up 17% over last year for 9M FY26
- 3
EBITDA for the quarter was Rs. 18,164 mn, up 31% YoY for Q3 FY26
- 4
EBITDA margin for the quarter stood at 26.5%, which is an improvement of 20 bps on a YoY basis for Q3 FY26
- 5
Net Profit (Adjusted)' for the quarter was Rs. 11,109 mn, up 9% YoY for Q3 FY26
- 6
Capex (organic) for the quarter was Rs. 4,637 mn for Q3 FY26
- 7
R&D investments for the quarter stood at Rs. 6,074 mn (8.8% of revenues) for Q3 FY26
- 8
Net Debt to Equity ratio as on 31t December 2025 was 0.11x while Net Debt to EBITDA stood at 0.36x at the end of December 2025
Management Comments
Dr. Sharvil Patel
Managing Director - Zydus Lifesciences Limited
Our robust performance in 3QFY26 across key businesses reinforces the strength and scalability of our base business. Our disciplined M&A and business development strategy is translating into tangible results, laying a strong foundation for sustained value creation. Anchored in patient centricity, supported by unwavering compliance and an agile supply chain, we continue to deliver quality products globally. We remain focused on consistent execution and driving long-term shareholder value.
Informational and educational content only. Not investment advice.